The National Institutes of Health has awarded Lucigen a $150,000 Small Business Innovation Research grant to be used to develop research tools with the potential to improve human health. The grant provides funding for the development of improved tools for “RNA-Seq” techniques used in next generation sequencing applications. RNA-Seq methods are employed in order to study gene regulation and expression; however, current methods suffer from poor accuracy and inherent bias. Lucigen’s portfolio of high-fidelity reverse-transcriptase polymerases, along with the company’s experience in constructing low-bias DNA libraries, will be utilized to create new methods for accurate RNA-Seq applications. The result will enable scientists to gain clearer understanding of gene regulation and subsequently apply this to human health.
Grant awarded to evaluate the effectiveness of comparative RNA-seq analysis within the clinical process
8 days ago
SomaGenics Receives Award or Allowance of Four Patents Covering Its Small RNA Analysis and Therapeutics
28 days ago
December 12, 2017